Equillium, Inc. (NASDAQ: EQ) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Equillium, Inc. (NASDAQ: EQ) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $3.00.
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis [Yahoo! Finance]